Lincoln Pharmaceuticals Ltd

Lincoln Pharma., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This development comes amid a backdrop of subdued financial performance and challenging market conditions, prompting a reassessment of the company’s standing within its sector.

Lincoln Pharmaceuticals has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces and indicator signals. Recent evaluation adjustments reveal a transition from mildly bearish to bearish technical trends, underscoring a nuanced market assessment for this Pharmaceuticals & Biotechnology sector stock.

Lincoln Pharmaceuticals has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish indicators across multiple timeframes. Recent market data reveals a mild transition in trend dynamics, with key technical parameters signalling a cautious outlook for investors in the Pharmaceuticals & Biotechnology sector.

Lincoln Pharmaceuticals has experienced a notable shift in its technical parameters, reflecting a transition in price momentum and mixed signals from key technical indicators. The stock’s current price stands at ₹529.05, slightly below its previous close of ₹531.90, with a day’s trading range between ₹527.60 and ₹534.55. This movement comes amid a broader technical trend adjustment from mildly bearish to bearish, signalling evolving market sentiment within the Pharmaceuticals & Biotechnology sector.

Lincoln Pharmaceuticals has recently revised its evaluation amid current market dynamics, with its stock price rising from the previous close. Over the past year, the company has faced a decline, contrasting with broader market gains. Despite short-term pressures, it has shown strong long-term performance compared to the Sensex.

Lincoln Pharmaceuticals Ltd. reported a disappointing second quarter for fiscal year 2026, with net profit plummeting 24.12% year-on-year to ₹19.98 crores despite modest revenue growth. The Ahmedabad-based pharmaceutical manufacturer, with a market capitalisation of ₹1,032.53 crores, saw its shares trading at ₹515.50 as of November 14, 2025, reflecting investor concerns about deteriorating profitability and operational challenges.

Lincoln Pharmaceuticals has reached a new 52-week low of Rs. 491, reflecting a significant decline in stock performance. The company has underperformed its sector and is trading below all major moving averages. Over the past year, it has seen a notable decline, contrasting with broader market gains.

Lincoln Pharmaceuticals, a microcap in the Pharmaceuticals & Biotechnology sector, has faced a challenging year with a return of -21.17%. Despite recent difficulties, the company has shown resilience over five years, achieving a 137.11% return, outperforming the Sensex's 93.02% during the same period.

Lincoln Pharmaceuticals has recently revised its evaluation amid current market conditions. The stock is priced at 524.65, reflecting a decline over the past year. Despite recent challenges, the company has demonstrated resilience with a significant 145.62% return over five years, outperforming the Sensex.

Lincoln Pharmaceuticals has recently revised its evaluation amid changing market conditions. The stock is priced at 525.00, reflecting a year-long decline of 19.93%. Despite recent challenges, the company has demonstrated resilience with a 231.02% return over the past decade, surpassing the Sensex's 206.55% return.